HomeNewsBusinessBuy Shalby; target of Rs 170: ICICI Direct

Buy Shalby; target of Rs 170: ICICI Direct

ICICI Direct is bullish on Shalby has recommended buy rating on the stock with a target price of Rs 170 in its research report dated February 07, 2021.

February 07, 2022 / 19:31 IST
Story continues below Advertisement

ICICI Direct's research report on Shalby

Started by renowned orthopaedic surgeon Dr Vikram Shah, Shalby is a multi-specialty hospitals chain with expertise in joint replacement. Therapy-wise breakup Q3FY22: anthroplasty:38%, critical care & general medicine: 11%, orthopaedic: 9%, oncology:10%, cardiac science:10%, neurology 6%, nephrology:3%, others:13% Shalby registered a blended ARPOB of Rs 32,049 and ALOS of 4.02 days (without day care procedures) in Q3FY22 Acquisition of US based Consensus to diversify into related implant business besides supporting arthroplasty and orthopaedic segments

Story continues below Advertisement

Outlook

Upgrade from HOLD to BUY due to 1) consistency in operational performance from hospitals, 2) visible RoIC improvement by FY24, 3) focus on asset light model via franchisee push, 4) foray into implants likely to provide integration advantage and third party push We value Shalby at Rs 170 based on SOTP valuation